Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Healthcare Shares
Doomed takeover bid for Mayne Pharma to come to an end
Share Fallers
Why Accent Group, EOS, Mayne Pharma, and Pilbara Minerals shares are falling today
Share Fallers
Why Alliance Aviation, Brainchip, Mayne Pharma, and Perpetual Credit shares are sinking today
Share Fallers
Why Aeris Resources, Humm, Mayne Pharma, and Steadfast shares are sinking today
Healthcare Shares
All Ords drug maker's shares plunge 30% on takeover troubles
Share Gainers
Why AMP, GQG, Jumbo, and Mayne Pharma shares are racing higher today
Industrials Shares
Here's a potential double-digit trade gain, following Mayne Pharma's takeover court win
Share Fallers
Why Mayne Pharma, Metal Powder Works, Smartgroup, and Super Retail shares are dropping today
How to invest
Australian billionaires: Which stocks do they own?
Share Gainers
Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today
Share Gainers
Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today
Share Fallers
Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
